Free website hits

Good morning, everyone, and how are you today? We are doing just fine, thank you, courtesy of sunny skies and mild breezes hovering over the Pharmalot campus. Moreover, the short person is quietly hunched over a laptop and the official mascot has left for a much-needed constitutional. This makes it possible for us to tend to the matters at hand. We will, however, take a brief detour today to chat about drug pricing with former Gilead Sciences chief operating officer Jim Meyers at 1 p.m. ET, and STAT+ subscribers are invited to tune in. Meanwhile, here are a few tidbits. Hope your day goes well and you remain safe. Remember, wear a mask. …

The European Commission is likely to give final authorization for the roll-out of Covid-19 vaccines days after the European Medicines Agency issues approvals, Reuters tells us. The EMA plans to decide on whether to approve the vaccine being developed by Pfizer (PFE) and BioNTech (BNTX) by Dec. 29, and the shot being developed by Moderna (MRNA) by Jan. 12. Under EU rules, EMA recommends the authorization of a drug or vaccine and the EU Commission authorizes them on the basis of EMA scientific advice.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]